A randomized, open-label, single-dose, 3-period crossover, pharmacokinetic study designed to compare the systemic des-ciclesonide exposure of OMNARIS (ciclesonide) nasal spray, ciclesonide HFA [hydrofluoroalkane] nasal aerosol, and orally inhaled ciclesonide.
Latest Information Update: 04 Mar 2022
At a glance
- Drugs Ciclesonide (Primary) ; Ciclesonide (Primary)
- Indications Allergic rhinitis
- Focus Pharmacokinetics
- Sponsors Covis Pharma
- 08 Feb 2022 Trial focus changed from TU to PK, as the primary endpoint was amended
- 07 Jun 2011 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 18 Mar 2008 Results presented at AAAAI in 2008